Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | VDR | P11473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17662653 | 0.85 | USP2 (0.33) | USP2 | |
| SCHEMBL8083397 | 0.81 | MAPK1 (0.56) | MAPK1USP2ARVDR | |
| SCHEMBL116799 | 0.81 | MAPK1 (0.56) | MAPK1USP2ARVDR | |
| SCHEMBL12083370 | 0.81 | MAPK1 (0.56) | MAPK1USP2ARVDR | |
| Hydrochloric Acid SCHEMBL8201302 | 0.79 | MAPK1 (0.54) | MAPK1USP2AR | |
| SCHEMBL18271813 | 0.78 | ALDH1A1 (0.40) | MAPK1USP2ARVDR | |
| SCHEMBL17664915 | 0.78 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL24754807 | 0.76 | KDM4E (0.31) | USP2ARVDR | |
| SCHEMBL10420136 | 0.76 | USP2 (0.50) | USP2VDR | |
| SCHEMBL2467812 | 0.75 | USP2 (0.39) | MAPK1USP2ARVDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464874-B2 | Fluorinated tensides | MERCK PATENT GMBH (DE) | 2019-11-05 | — | — | US | disclosed |
| US-20170121260-A1 | FLUORINATED TENSIDES | MERCK PATENT GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
| WO-2015124290-A1 | FLUORINATED TENSIDES | MERCK PATENT GMBH (DE) | 2015-08-27 | — | — | WO | disclosed |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080290-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121260-A1 | FLUORINATED TENSIDES | FLNA, KCNN3, FLNB | MAPK1 3036/4885USP2 3824/4885AR 4787/4885 |
| US-10464874-B2 | Fluorinated tensides | FLNA, KCNN3, FLNB | MAPK1 3036/4885USP2 3824/4885AR 4787/4885 |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PIK3CA, PTEN | MAPK1 208/4885USP2 2226/4885AR 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.